More articles from 05.01 - Airway pharmacology and treatment

Lung inhalation-on-chip: A triple co-culture cellular platform to predict toxicity of aerosolized toxicants
A Sengupta, W Hassan, N Roldan, J Stucki, T Krebs, O Wisser, N Hobi, O T Guenat

European Respiratory Journal Sep 2022, 60 (suppl 66) 3398; DOI: 10.1183/13993003.congress-2022.3398
EDAC PREVALENCE AND ASSOCIATED FACTORS IN PATIENTS WITH SEVERE BRONCHIAL ASTHMA
I Alfaya Fiaño, A J Solis Solis, F Andreo Garcia, P Serra Mitja, A Crespo Lessmann, A Torrego Fernández, D Ramos Barbón, T Zapata Comas, I Garcia Olivé, V Plaza Moral, A Rosell Gratacós, J Abad Capa, C Martínez Rivera

European Respiratory Journal Sep 2022, 60 (suppl 66) 3478; DOI: 10.1183/13993003.congress-2022.3478
Small mobile stem cells multitargeted approach to alveoli in vivo regeneration
A Rahmo

European Respiratory Journal Sep 2022, 60 (suppl 66) 3377; DOI: 10.1183/13993003.congress-2022.3377
Characteristics of Responders to Biologics in Patients with Severe Asthma: Based on Precision Medicine Intervention in Severe Asthma (PRISM) Study
J Lee, H Kim, J Jung, M Kim, J Choi, J Moon, S Y Park, S Kim, M Yang, B Kim, J Kwon, H Park, C S Park, T Lee, S Kim, Y Nam, H Park, B Lee, H Kwon, W Song, S W Lee, Y S Cho, T Kim

European Respiratory Journal Sep 2022, 60 (suppl 66) 3383; DOI: 10.1183/13993003.congress-2022.3383
The role of physical rehabilitation in the treatment of COPD
K Shvets, M Ostrovskyy, O Varunkiv, I Savelikhina, M Kulynych-Miskiv, G Korzh, N Korzh, K Ostrovska

European Respiratory Journal Sep 2022, 60 (suppl 66) 3494; DOI: 10.1183/13993003.congress-2022.3494
The anti-inflammatory and antifibrotic effects of a novel, pan-phosphodiesterase inhibitor in murine model of allergic asthma
K Wójcik-Pszczoła, K Pociecha, E Wyska, G Chłoń-Rzepa, H Plutecka, M Zadrożna, B Nowak, P Koczurkiewicz-Adamczyk, E Pękala, R Gosens

European Respiratory Journal Sep 2022, 60 (suppl 66) 3232; DOI: 10.1183/13993003.congress-2022.3232
Sphingosine-1-phosphate signaling pathway drives female asthma susceptibility
E Granato, I Cerqua, R Sorrentino, G Ferraro, M F Nanì, A Rossi, G Cirino, F Roviezzo

European Respiratory Journal Sep 2022, 60 (suppl 66) 3440; DOI: 10.1183/13993003.congress-2022.3440
Analysis of transport mechanisms of substances applied to the airways in a transparent airway model
C Cornelissen, A L Thiebes, M Dreher, S Gürzing, M Reddemann

European Respiratory Journal Sep 2022, 60 (suppl 66) 3441; DOI: 10.1183/13993003.congress-2022.3441
Pulmonary rehabilitation changes the oral microbiota of people with COPD
S Melo-Dias, M Cabral, A Furtado, S Souto-Miranda, J Carvo, A Mendes, C Almeida, A Marques, S Ana

European Respiratory Journal Sep 2022, 60 (suppl 66) 3487; DOI: 10.1183/13993003.congress-2022.3487
Severe asthma in obese patients: what to expect with Mepolizumab?
A Da Cunha Fonseca, D Machado, I Pascoal, I Franco, R Lima

European Respiratory Journal Sep 2022, 60 (suppl 66) 3216; DOI: 10.1183/13993003.congress-2022.3216

Main menu

User menu

Search

More articles from 05.01 - Airway pharmacology and treatment

Pages

Contact us